Akero Therapeutics, Inc.
AKRO
$54.63
-$0.06-0.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -292.82M | -283.96M | -269.44M | -252.06M | -237.22M |
| Total Depreciation and Amortization | 15.00K | 16.00K | 17.00K | 18.00K | 5.00K |
| Total Amortization of Deferred Charges | 717.00K | 702.00K | 673.00K | 607.00K | 553.00K |
| Total Other Non-Cash Items | 25.05M | 20.94M | 19.80M | 18.33M | 16.71M |
| Change in Net Operating Assets | 16.87M | 8.88M | -13.68M | 3.00M | 8.32M |
| Cash from Operations | -250.17M | -253.42M | -262.63M | -230.11M | -211.64M |
| Capital Expenditure | 0.00 | 0.00 | -999.00K | -999.00K | -999.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -330.79M | -314.50M | -648.74M | -108.71M | -111.20M |
| Cash from Investing | -330.79M | -314.50M | -649.74M | -109.71M | -112.19M |
| Total Debt Issued | 0.00 | 0.00 | 0.00 | 10.00M | 10.00M |
| Total Debt Repaid | -37.40M | -- | -- | -- | -- |
| Issuance of Common Stock | 478.93M | 478.69M | 475.59M | 436.69M | 361.20M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -605.00K | -669.00K | -1.15M | -844.00K | -846.00K |
| Cash from Financing | 440.93M | 478.02M | 474.44M | 445.85M | 370.36M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -140.03M | -89.91M | -437.93M | 106.03M | 46.52M |